Rethinking Clinical Trials

FEBRUARY 14, 2024

Both drugs have a well-established safety profile and would be a good fit for a pragmatic design. The study started in June 2016 and ended in June 2022 and ultimately found no difference between the 2 drugs in preventing major CV outcomes and non-cancer death among hypertensive VA patients.

Clinical Trials 152

Clinical Trials Clinical Trials Cardiology Trials 152

World of DTC Marketing

AUGUST 16, 2020

I have seen first hand how the drugs we market can save lives and lead to a better quality of life for millions. When I first started in the industry DTC was fairly new as we launched a number of groundbreaking drugs such as statins. I observed people who were able to launch groundbreaking initiatives leave the industry.

Sales 196

Sales Drugs Insulin Development 196

pharmaphorum

NOVEMBER 13, 2020

Part of this strategy saw the launch of new digital platforms, including e-commerce. Each country has different regulations in regard to the online advertising of prescription drugs and over-the-counter medicines. As with Google, use target keywords relevant to your audience. How to make the move from physical to digital.

Branding 124

Branding Pharmacy Marketing Compliance 124

Rethinking Clinical Trials

SEPTEMBER 22, 2022

The COlchicine Hypertension Trial (COHERENT) is a pragmatic Phase II trial that looked at only hypertension by using registry data to identify patients that receive at least two hypertension drugs. Faculty of Health and Medical Sciences. University of Copenhagen. Head of Cardiovascular Non-Invasive Imaging Research Laboratory. Key Points.

Trials 130

Trials Cardiology Vaccination Vaccine 130